Impact of Rapidly Deployed COVID-19 Monoclonal Antibody Infusion Clinics on Rate of Hospitalization
MD Bronson E Delasobera, MD Tara Saggar, MBA Jennifer N Goodwin, MS, PA-C, Amanda Joy, DNP Kiersten N Henry, Acnp-Bc, PharmD, MBA Bonnie Levin, MD David D Hager, MD Joel Mcalduff, PhD Sameer Desale, MHSA Xavier Owens, MD Glenn W Wortmann, MD Princy N Kumar
Background: Providing monoclonal antibody therapy infusions requires challenging logistics, resources, and technology, hindering availability across the United States. Early identification and treatment of COVIDpositive patients can reduce hospitalizations. Objective: This study aimed to describe the referral, selection process, and deployment of outpatient monoclonal infusion clinics, as well as the impact of monoclonal antibody therapy in COVID-positive patients on the rate of emergency department (ED) visits and hospitalization. Methods: This is a retrospective cohort study that used screening of all COVID-positive ambulatory patients using a unique scoring rubric embedded in the emergency medical response for appropriateness for therapy between November 2020 and January 2021. Participants included all outpatients testing positive for COVID-19 were screened, and those eligible were referred for treatment with bamlanivimab. Of the 443 patients referred for treatment, 252 patients were treated with bamlanivimab compared with 191 patients who declined treatment. Patients were treated either in 1 of the 2 outpatient infusion centers (74%) or the ED (26%.) Results: Of 443 patients with positive COVID-19 diagnoses who were eligible for treatment based on a risk assessment rubric, 252 received bamlanivimab. There was a significant reduction in hospitalization of the treatment versus control group (6.7% vs 13.6%, P < 0.05). No significant differences were noted in risk score at screening, ED visits after infusion, days of symptom onset at screening or infusion, or death.
Conclusions and Relevance: The efficacy of monoclonal antibody therapy on reducing hospitalization was demonstrated. Rapid development of screening technology, scheduling and operational logistics, and physical space can overcome the challenges in the current environment.
References
Chen, Nirula, Heller, SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19, N Engl J Med
Fineberg, Rapid Expert Consultation on Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics,
doi:10.17226/26063Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Kumar, Wu, Stosor, Real-world experience of bamlanivimab for COVID-19: a case-control study, Clin Infect Dis,
doi:10.1093/cid/ciab305Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19, N Engl J Med
Williamson, Tewarson, Increasing utilization of COVID-19 monoclonal antibodies: considerations and promising practices for states
{ 'indexed': {'date-parts': [[2022, 1, 28]], 'date-time': '2022-01-28T06:56:28Z', 'timestamp': 1643352988200},
'reference-count': 4,
'publisher': 'Ovid Technologies (Wolters Kluwer Health)',
'issue': '2',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'short-container-title': ['Infect Dis Clin Pract'],
'published-print': {'date-parts': [[2022, 3]]},
'DOI': '10.1097/ipc.0000000000001109',
'type': 'journal-article',
'created': {'date-parts': [[2022, 1, 26]], 'date-time': '2022-01-26T18:00:08Z', 'timestamp': 1643220008000},
'page': '1-6',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': [ 'Impact of Rapidly Deployed COVID-19 Monoclonal Antibody Infusion Clinics on Rate of '
'Hospitalization'],
'prefix': '10.1097',
'volume': '30',
'author': [ {'given': 'Bronson E.', 'family': 'Delasobera', 'sequence': 'first', 'affiliation': []},
{'given': 'Tara', 'family': 'Saggar', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jennifer N.', 'family': 'Goodwin', 'sequence': 'additional', 'affiliation': []},
{'given': 'Amanda', 'family': 'Joy', 'sequence': 'additional', 'affiliation': []},
{'given': 'Kiersten N.', 'family': 'Henry', 'sequence': 'additional', 'affiliation': []},
{'given': 'Bonnie', 'family': 'Levin', 'sequence': 'additional', 'affiliation': []},
{'given': 'David D.', 'family': 'Hager', 'sequence': 'additional', 'affiliation': []},
{'given': 'Joel', 'family': 'McAlduff', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sameer', 'family': 'DeSale', 'sequence': 'additional', 'affiliation': []},
{'given': 'Xavier', 'family': 'Owens', 'sequence': 'additional', 'affiliation': []},
{'given': 'Glenn W.', 'family': 'Wortmann', 'sequence': 'additional', 'affiliation': []},
{'given': 'Princy N.', 'family': 'Kumar', 'sequence': 'additional', 'affiliation': []}],
'member': '276',
'published-online': {'date-parts': [[2022, 1, 27]]},
'reference': [ { 'key': 'bib1-20220127',
'doi-asserted-by': 'crossref',
'first-page': '229',
'DOI': '10.1056/NEJMoa2029849',
'article-title': 'SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19',
'volume': '384',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': 'bib2-20220127',
'first-page': '238',
'article-title': 'REGN-COV2, a neutralizing antibody cocktail, in outpatients with '
'COVID-19',
'volume': '384',
'year': '2020',
'journal-title': 'N Engl J Med'},
{ 'key': 'bib5-20220127',
'article-title': 'Real-world experience of bamlanivimab for COVID-19: a case-control '
'study',
'volume': 'ciab305',
'year': '2021',
'journal-title': 'Clin Infect Dis'},
{ 'issue': '7',
'key': 'bib6-20220127',
'doi-asserted-by': 'crossref',
'first-page': '632',
'DOI': '10.1001/jama.2021.0202',
'article-title': 'Effect of bamlanivimab as monotherapy or in combination with etesevimab '
'on viral load in patients with mild to moderate COVID-19: a randomized '
'clinical trial',
'volume': '325',
'year': '2021',
'journal-title': 'JAMA'}],
'container-title': ['Infectious Diseases in Clinical Practice'],
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://journals.lww.com/10.1097/IPC.0000000000001109',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 1, 27]],
'date-time': '2022-01-27T09:00:25Z',
'timestamp': 1643274025000},
'score': 1,
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 1, 27]]},
'references-count': 4,
'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2022]]}},
'URL': 'http://dx.doi.org/10.1097/ipc.0000000000001109',
'relation': {},
'ISSN': ['1536-9943', '1056-9103'],
'issn-type': [{'value': '1536-9943', 'type': 'electronic'}, {'value': '1056-9103', 'type': 'print'}],
'subject': ['Infectious Diseases', 'Microbiology (medical)'],
'published': {'date-parts': [[2022, 1, 27]]}}
